Acne Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pha

DelveInsight's "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acne Vulgaris, historical and forecasted epidemiology as well as the Acne Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acne Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acne Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Acne Vulgaris Market Report:
• The Acne Vulgaris market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2023, Ascletis Pharma initiated a Phase III clinical trial for ASC40 (Denifanstat), its drug candidate designed to address moderate to severe acne vulgaris in China. This trial, which is multicenter, double-blind, randomized, and placebo-controlled, aims to evaluate the effectiveness and safety of ASC40.
• In December 2023, Dermata Therapeutics initiated enrollment of the initial participant in the Phase III STAR-1 clinical trial for its topical product candidate, DMT310, aimed at managing moderate-to-severe acne. STAR-1 represents the primary of two Phase III investigations in the DMT310 Phase III clinical program, focusing on evaluating the safety, effectiveness, and tolerability of the product among individuals with facial acne.
• BPX-01, DP-120, GT20029, and other promising treatments are showing encouraging top-line outcomes in their clinical trials. These emerging therapies are currently in the middle phase of clinical development and are poised for launch, which will significantly strengthen the pipeline.
• According to Skroza et al. (2018), an analysis of data from the acne outpatient database revealed that, among adults, 85% of patients were female and 15% were male. This indicates that female sex is more common. Among the teenagers, 53% of the patients were female and 47% were male
• A brand-new, exclusive topical minocycline gel formulation (BPX-01) is being developed by BioPharmX to treat acne vulgaris. The product is the initial contender from the company's hydrophilic anhydrous topical administration technology, and the minocycline is fully soluble in our formulation. The formulation is presently being developed clinically for individuals with acne vulgaris inflammatory lesions.
• Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others
• Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others
• The Acne Vulgaris epidemiology based on gender analyzed that females are predominantly affected compared to males
• The Acne Vulgaris market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acne Vulgaris pipeline products will significantly revolutionize the Acne Vulgaris market dynamics.
Acne Vulgaris Overview
Acne vulgaris, commonly known as acne, is a chronic skin condition characterized by the formation of pimples, blackheads, whiteheads, cysts, and nodules. It typically occurs when hair follicles become clogged with oil and dead skin cells, leading to the growth of bacteria known as Propionibacterium acnes. Acne commonly appears on the face, neck, chest, back, and shoulders.

Get a Free sample for the Acne Vulgaris Market Report:
https://www.delveinsight.com/report-store/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acne Vulgaris Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acne Vulgaris Epidemiology Segmentation:
The Acne Vulgaris market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Acne Vulgaris
• Prevalent Cases of Acne Vulgaris by severity
• Gender-specific Prevalence of Acne Vulgaris
• Diagnosed Cases of Episodic and Chronic Acne Vulgaris

Download the report to understand which factors are driving Acne Vulgaris epidemiology trends @ Acne Vulgaris Epidemiology Forecast
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acne Vulgaris Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acne Vulgaris market or expected to get launched during the study period. The analysis covers Acne Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acne Vulgaris Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acne Vulgaris Therapies and Key Companies
• BPX-01: BioPharmX
• IDP-120: Bausch Health Americas, Inc.
• GT20029: Kintor Pharma
• KX-826: KintorPharma
• S6G5T-3: Sol-Gel Technologies, Ltd.
• ASC40: Ascletis Pharma
• GK530G: Galderma R&D
• Dapsone: Torrent Pharma
• DMT310: Dermata Therapeutics
• CD5789 (trifarotene): Galderma R&D
• Afamelanotide: Clinuvel Pharma
• NVN1000: Novan, Inc.
• Hydrogen Peroxide: Dermata Therapeutics
• Trifarotene Cream: Galderma R&D
• S6G5T-3: Accelovance
• GDC 268 Lotion: Balmoral Medical
• Isotretinoin: Vyne Therapeutics Inc.
• gevokizumab: XOMA (US) LLC
• BLI1100: Braintree Laboratories
• AKLIEF®: Teva Pharma
• Imsidolimab: AnaptysBio, Inc.
• RA-18C3: Janssen Research
• FMX101: Cutia Therapeutics
• IDP-126: Bausch Health

Discover more about therapies set to grab major Acne Vulgaris market share @ Acne Vulgaris Treatment Market
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Acne Vulgaris Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others
• Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others
• Acne Vulgaris Therapeutic Assessment: Acne Vulgaris current marketed and Acne Vulgaris emerging therapies
• Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acne Vulgaris Unmet Needs, KOL's views, Analyst's views, Acne Vulgaris Market Access and Reimbursement

To know more about Acne Vulgaris companies working in the treatment market, visit @ Acne Vulgaris Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acne Vulgaris Market Report Introduction
2. Executive Summary for Acne Vulgaris
3. SWOT analysis of Acne Vulgaris
4. Acne Vulgaris Patient Share (%) Overview at a Glance
5. Acne Vulgaris Market Overview at a Glance
6. Acne Vulgaris Disease Background and Overview
7. Acne Vulgaris Epidemiology and Patient Population
8. Country-Specific Patient Population of Acne Vulgaris
9. Acne Vulgaris Current Treatment and Medical Practices
10. Acne Vulgaris Unmet Needs
11. Acne Vulgaris Emerging Therapies
12. Acne Vulgaris Market Outlook
13. Country-Wise Acne Vulgaris Market Analysis (2019-2032)
14. Acne Vulgaris Market Access and Reimbursement of Therapies
15. Acne Vulgaris Market Drivers
16. Acne Vulgaris Market Barriers
17. Acne Vulgaris Appendix
18. Acne Vulgaris Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Acne Vulgaris Pipeline https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Acne Vulgaris Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acne Vulgaris market. A detailed picture of the Acne Vulgaris pipeline landscape is provided, which includes the disease overview and Acne Vulgaris treatment guidelines.
Acne Vulgaris Epidemiology https://www.delveinsight.com/report-store/acne-vulgaris-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acne Vulgaris Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Acne Vulgaris epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports Offered By DelveInsight:

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.